Abstract
This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.
References
Feb 10, 1988·Journal of Immunological Methods·B B Cohen
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Feb 13, 2001·Progress in Neurobiology·R E BrownH L Haas
May 17, 2001·Schizophrenia Bulletin·T L PattersonD V Jeste
May 13, 2005·Schizophrenia Bulletin·Robert W BuchananSteve R Marder
Mar 14, 2007·Pharmaceutical Statistics·Peter Lane
May 6, 2009·British Journal of Pharmacology·C Y JinP Panula
Dec 16, 2011·Trends in Cognitive Sciences·Deanna M Barch, Alan Ceaser
Mar 26, 2013·Current Alzheimer Research·Pradeep J NathanRobert Lai
Mar 26, 2013·Schizophrenia Research·Michael F EganDavid Michelson
Oct 29, 2013·Bioorganic & Medicinal Chemistry Letters·David M WilsonAndrew D Medhurst
Nov 26, 2013·Bioorganic & Medicinal Chemistry Letters·David M WilsonAndrew D Medhurst
Dec 24, 2013·Current Alzheimer Research·Richard A GroveJoseph P Horrigan
Feb 12, 2014·Schizophrenia Bulletin·George M HaigRobert A Lenz
Mar 29, 2014·British Journal of Pharmacology·S AshworthV J Cunningham
Citations
Aug 19, 2015·Neuropharmacology·Maximiliano Rapanelli, Christopher Pittenger
Apr 10, 2016·Neuropharmacology·Jean-Charles Schwartz, Jeanne-Marie Lecomte
Apr 12, 2017·CNS Drugs·Joshua T Kantrowitz
May 20, 2017·Expert Opinion on Drug Discovery·Mitsuyuki MatsumotoKatsunori Tajinda
Jan 12, 2017·Evidence-based Mental Health·Sven Trelle
Apr 24, 2018·PloS One·Ce ChenCheng-Ge Gao
Dec 27, 2018·Chemical Biology & Drug Design·Nakisa GhamariMaryam Hamzeh-Mivehroud
Jan 18, 2018·Expert Opinion on Therapeutic Patents·Dorota Łażewska, Katarzyna Kieć-Kononowicz
Apr 5, 2016·Annals of the New York Academy of Sciences·Annette B Brühl, Barbara J Sahakian
Mar 14, 2019·Current Opinion in Neurology·David KremerPatrick Küry
Aug 4, 2020·British Journal of Pharmacology·Takeo YoshikawaKazuhiko Yanai
Dec 19, 2017·PloS One·Yongfeng ChenRyan Wang
Oct 3, 2018·Multiple Sclerosis : Clinical and Laboratory Research·David KremerRanjan Dutta
Nov 27, 2016·Journal of Neurology·Caryl J SchwartzbachDouglas L Arnold
Jun 30, 2019·Current Treatment Options in Neurology·Lindsey WooliscroftDennis Bourdette
Apr 30, 2020·Life·Pakhuri MehtaSławomir Filipek
Jul 13, 2019·Neuropharmacology·Stephen J KaarOliver D Howes
May 1, 2021·Life·Nadjet Gacem, Brahim Nait-Oumesmar
Jun 5, 2021·Drugs·Niklas HuntemannSven G Meuth
Aug 3, 2021·Frontiers in Neuroscience·Elliott Carthy, Tommas Ellender